Meridian Biotech
Live nowDiagnostic assays manufactured for tropical disease burden
Demonstration content. Illustrative sample data — these are not live offers. Company names, figures, and dates are fictional placeholders for demonstration.
Book progress
About Meridian Biotech
Meridian develops and manufactures rapid diagnostic assays calibrated to the disease profile of West African clinical practice, rather than importing kits validated elsewhere.
Revenue comes from assay sales to hospital groups and public health programmes, with a growing share from a reagent subscription that locks in repeat volume.
Offer terms
Use of proceeds
Cap table after the raise
What this subscription returns
Registered in your name in the depository, then admitted to the ContiSX secondary market after settlement — subject to the 180 days from admission lock-up.
An advanced loyalty reward credited at allotment — transferable, interoperable, and listed on a partner digital exchange platform.
Who runs the company
Documents
Document downloads are inactive in this demonstration.
Key risk factors
Capital is at risk. Equity in early-stage companies is illiquid and may lose value. Read the offer document in full before subscribing to any real offering.